- Home
- ARMP vs EDAP Comparison
ARMP vs EDAP Comparison
Compare ARMP & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- EDAP
- Stock Information
- Founded
- ARMP N/A
- EDAP 1979
- Country
- ARMP United States
- EDAP France
- Employees
- ARMP N/A
- EDAP N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ARMP Health Care
- EDAP Health Care
- Exchange
- ARMP Nasdaq
- EDAP Nasdaq
- Market Cap
- ARMP 80.0M
- EDAP 94.2M
- IPO Year
- ARMP N/A
- EDAP 1997
- Fundamental
- Price
- ARMP $2.72
- EDAP $2.47
- Analyst Decision
- ARMP Strong Buy
- EDAP Strong Buy
- Analyst Count
- ARMP 1
- EDAP 2
- Target Price
- ARMP $7.00
- EDAP $14.00
- AVG Volume (30 Days)
- ARMP 8.3K
- EDAP 207.0K
- Earning Date
- ARMP 11-13-2024
- EDAP 11-07-2024
- Dividend Yield
- ARMP N/A
- EDAP N/A
- EPS Growth
- ARMP N/A
- EDAP N/A
- EPS
- ARMP N/A
- EDAP N/A
- Revenue
- ARMP $3,719,000.00
- EDAP $70,722,730.00
- Revenue This Year
- ARMP N/A
- EDAP $8.00
- Revenue Next Year
- ARMP $83.33
- EDAP $14.58
- P/E Ratio
- ARMP N/A
- EDAP N/A
- Revenue Growth
- ARMP N/A
- EDAP 12.17
- 52 Week Low
- ARMP $1.93
- EDAP $2.27
- 52 Week High
- ARMP $4.48
- EDAP $8.50
- Technical
- Relative Strength Index (RSI)
- ARMP 67.03
- EDAP 43.12
- Support Level
- ARMP $2.21
- EDAP $2.50
- Resistance Level
- ARMP $2.96
- EDAP $2.72
- Average True Range (ATR)
- ARMP 0.15
- EDAP 0.17
- MACD
- ARMP 0.05
- EDAP -0.01
- Stochastic Oscillator
- ARMP 68.42
- EDAP 27.27
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.